~ Buy the PIQRAY (alpelisib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR PIQRAY

All Clinical Trials for Piqray

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02379247 ↗	BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer	Active, not recruiting	Novartis Pharmaceuticals	Phase 1/Phase 2	2015-02-01	Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
NCT02379247 ↗	BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer	Active, not recruiting	Priyanka Sharma	Phase 1/Phase 2	2015-02-01	Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
NCT02379247 ↗	BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer	Active, not recruiting	University of Kansas Medical Center	Phase 1/Phase 2	2015-02-01	Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
NCT03207529 ↗	Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer	Recruiting	Astellas Pharma Global Development, Inc.	Phase 1	2019-06-07	This phase I trial studies the side effects and best dose of alpelisib when given together with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer that has spread to other places in the body. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgen receptor can cause the growth of breast cancer cells. Hormone therapy using enzalutamide may fight breast cancer by lowering the amount of androgen the body makes. Giving alpelisib and enzalutamide may work better in treating patients with breast cancer.
NCT03207529 ↗	Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1	2019-06-07	This phase I trial studies the side effects and best dose of alpelisib when given together with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer that has spread to other places in the body. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgen receptor can cause the growth of breast cancer cells. Hormone therapy using enzalutamide may fight breast cancer by lowering the amount of androgen the body makes. Giving alpelisib and enzalutamide may work better in treating patients with breast cancer.

Clinical Trial Conditions for Piqray

Condition Name

Condition Name for Piqray
Intervention	Trials
Breast Cancer	7
Metastatic Breast Cancer	4
Triple-Negative Breast Carcinoma	2
Anatomic Stage III Breast Cancer AJCC v8	2

Condition MeSH

Condition MeSH for Piqray
Intervention	Trials
Breast Neoplasms	14
Carcinoma	3
Neoplasms	2
Insulin Resistance	1

Clinical Trial Locations for Piqray

Trials by Country

Trials by Country for Piqray
Location	Trials
United States	31
Argentina	1
Mexico	1
Brazil	1
Australia	1

Trials by US State

Trials by US State for Piqray
Location	Trials
New York	3
Missouri	3
Texas	3
Maryland	2
California	2

Clinical Trial Progress for Piqray

Clinical Trial Phase

Clinical Trial Phase for Piqray
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	6
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for Piqray
Clinical Trial Phase	Trials
Not yet recruiting	10
Recruiting	5
Active, not recruiting	1

Clinical Trial Sponsors for Piqray

Sponsor Name

Sponsor Name for Piqray
Sponsor	Trials
Novartis	4
National Cancer Institute (NCI)	2
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type for Piqray
Sponsor	Trials
Industry	15
Other	15
NIH	2